Simulations Plus, Inc. (NASDAQ:SLP) Receives $25.00 Average Target Price from Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned a consensus rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $25.00.

A number of brokerages recently commented on SLP. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Zacks Research upgraded Simulations Plus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 28th. TD Cowen reaffirmed a “hold” rating on shares of Simulations Plus in a research report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Simulations Plus in a research report on Wednesday, October 8th. Finally, BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th.

Simulations Plus Stock Up 0.8%

Simulations Plus stock opened at $20.43 on Friday. The company has a market capitalization of $411.66 million, a PE ratio of -6.38 and a beta of 1.09. Simulations Plus has a 12-month low of $12.39 and a 12-month high of $37.67. The firm’s fifty day moving average is $18.70 and its 200 day moving average is $16.37.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. The company had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.05 million. During the same period last year, the firm posted $0.17 earnings per share. Sell-side analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Simulations Plus

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Simulations Plus by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after buying an additional 390 shares in the last quarter. Prudential Financial Inc. increased its stake in Simulations Plus by 5.7% in the 2nd quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock worth $300,000 after acquiring an additional 930 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Simulations Plus by 3.8% in the 2nd quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock valued at $636,000 after acquiring an additional 1,323 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Simulations Plus by 2.1% in the 1st quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock valued at $1,624,000 after acquiring an additional 1,334 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Simulations Plus during the second quarter valued at approximately $25,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.